Akari Therapeutics, Plc Securities Litigation

According to the law firm press release, the complaint filed in this class action lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company\'s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company\'s CEO, and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; (2) that the Company lacked adequate checks and protections to prevent such behavior; and (3) that, as a result of the foregoing, Defendants\' statements about Akari\'s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

See Case Details »

Lion Biotechnologies, Inc. Securities Litigation

According to the law firm press release, the lawsuit alleges defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that (1) Lion Biotechnologies, through its former CEO, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion Biotechnologies to potential investors that purported to be independent from the company when, in fact, they were paid promotions; (2) the former CEO engaged a notorious stock promotion firm to pay writers to publish articles about Lion Biotechnologies on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) the former CEO actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion Biotechnologies was indirectly compensating them for their publications; and (4) as a result, defendants\\\\' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

See Case Details »

Celadon Group, Inc. Securities Litigation

According to the law firm press release, the lawsuit alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Celadon's equity contribution to its joint venture with Element Financial Corp. was $68.2 million, rather than the $100 million contribution as reported in its public filings; (2) Celadon is being actively investigated by the SEC; (3) Celadon's financial statement for the fiscal year ended June 30, 2016 could not be relied upon; (4) Celadon's financial statement for quarter ended September 30, 2016 could not be relied upon; (5) Celadon's financial statement for quarter ended December 31, 2016 could not be relied upon; and (6) as a result, defendants' statements about Celadon's business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

See Case Details »

ImmunoCellular Therapeutics, Ltd. Securities Litigation

According to the law firm press release, ImmunoCellular is a development stage company, and its lead product candidate, ICT-107, is a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma multiforme.

See Case Details »

Alliance MMA, Inc. Securities Litigation

According to the law firm press release, the lawsuit alleges defendants in connection with Alliance MMA's initial public offering made false and/or misleading statements and/or failed to disclose that: (1) the condensed consolidated financial statements for the three months ended June 30, 2016 could not be relied upon because of an error in recognizing as compensation transfers of common stock by an affiliate of Alliance MMA to individuals who were at the time of transfer, or subsequently became, officers, directors or consultants of Alliance MMA; (2) the condensed consolidated financial statements for the six months ended June 30, 2016 could not be relied upon because of an error in recognizing as compensation transfers of common stock by an affiliate of Alliance MMA to individuals who were at the time of transfer, or subsequently became, officers, directors or consultants of Alliance MMA; and (3) as a result, defendants' statements about Alliance MMA's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

See Case Details »